Scarica l'app Stockscreener
19.08
0.63%
0.12
Dopo l'orario di chiusura:
19.08
Nuvectis Pharma Inc Borsa (NVCT) Ultime notizie
Behavioral Patterns of NVCT and Institutional Flows - Stock Traders Daily
Nuvectis Pharma (NASDAQ:NVCT) Shares Gap UpWhat's Next? - MarketBeat
Certain Common Stock of Nuvectis Pharma, Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2026. - marketscreener.com
Nuvectis Pharma (NVCT) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market Wi - The National Law Review
Nuvectis’ NXP800 Ovarian Cancer Trial Terminated: What Investors Should Watch Next - TipRanks
Soleus group (NVCT) discloses 1.65M-share, 5.1% Nuvectis Pharma stake - Stock Titan
HC Wainwright Boosts Earnings Estimates for Nuvectis Pharma - MarketBeat
(NVCT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Lucid Capital Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Raises Target Price to $34 - Moomoo
Nuvectis Pharma’s Heavy Reliance on Haisco Poses Major Operational and Geopolitical Risks - TipRanks
Nuvectis Pharma (NASDAQ:NVCT) Issues Earnings Results, Misses Estimates By $0.05 EPS - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Shares Gap Down After Earnings Miss - MarketBeat
Nuvectis Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Nuvectis Pharma, Inc. 2Q 2026: Net loss $(7.02)M, EPS $(0.30) — 10-Q Summary - TradingView
NVCT: Q2 2026 net loss widened to $7.0M; $106.3M raised in July extends cash runway for clinical development - TradingView
Nuvectis Pharma (NASDAQ: NVCT) boosts cash with $115M stock sale and new drug licenses - Stock Titan
Nuvectis Reports $7.0 Million Q2 Net Loss After Pipeline Deals - Quiver Quantitative
NVCT: Secured $115M financing, advanced late-stage pipeline, and reported higher R&D-driven net loss - TradingView
Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights - The Manila Times
NVCT Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know - Yahoo Finance
Nuvectis Pharma (NVCT) Expected to Announce Earnings on Tuesday - MarketBeat
Nuvectis Pharma Inc (NVCT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Nuvectis Pharma Inc (NVCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NVCT|Nuvectis Pharma Inc|Price:19.530|Chg%:+0.220 - TradingKey
NVCT|Nuvectis Pharma Inc|Price:19.310|Chg%:-0.840 - TradingKey
Nuvectis Pharma Inc (NVCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nuvectis Pharma Inc (NVCT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nuvectis Pharma Inc (NVCT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nuvectis Pharma Inc (NVCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nuvectis Pharma Inc (NVCT) Cash Flow - TradingKey
Nuvectis Pharma Inc (NVCT) Income Statement - TradingKey
Maxim Group Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Maintains Target Price $30 - Moomoo
H.C. Wainwright Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Maintains Target Price $39 - Moomoo
China approves Nuvectis’ ciprocopan for blood disorder PNH - Investing.com UK
Pantginis Reiterates Buy on Nuvectis, Citing Ciprocopan Approval and Pipeline Diversification; Price Target Maintained at $39 - TipRanks
Nuvectis’ NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor - TipRanks
Nuvectis' NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor - Benzinga
Correction: Nuvectis Announces Marketing Approval of Ciprocopan in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors - Investing News Network
Nuvectis Pharma Announces First Global Approval of Once-Daily Oral Complement Factor B Inhibitor Ciprocopan in China for PNH - Quiver Quantitative
Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors - GlobeNewswire
China approves ciprocopan, first oral once-dail... - Pluang
China approves Nuvectis’ ciprocopan for blood disorder PNH By Investing.com - Investing.com Australia
Nuvectis Pharma receives China approval for Ciprocopan to treat PNH in patients not given complement inhibitors - Traders Union
Nuvectis Drug Reached 12 g/dL in 59.5% of PNH Patients - Stock Titan
Nuvectis' NXP100 Just Achieved The First Marketing Approval Ever For A Once-Daily Oral Factor B Inhibitor - Menafn
NVCT Q1 2026 Earnings: EPS Beat Estimates as Company Advances PipelineEarnings Yield Analysis - dars.gov.et
Nuvectis Pharma Prices $100 Million Public Offering to Advance Pipeline - citybuzz -
Nuvectis Pharma Targets a $9.8 Billion Oral PNH Market With Late-Stage NXP100 - t.co
Wall Street analysts see a 61.46% upside in Nuvectis Pharma (NVCT): Can the stock really move this high? - MSN
StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data - Cantech Letter
Nuvectis Pharma expands into rare diseases with... - Pluang
Wall Street Wire: StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data - FinanzNachrichten.de
How (NVCT) Movements Inform Risk Allocation Models - Stock Traders Daily
Catalyst watch: SpaceX initiations, Sun Valley Conference, PepsiCo earnings - MSN
NVCT Stock Price, Quote & Chart - ChartMill
Nuvectis Pharma’s NXP900 Combo Trial Adds Fresh Momentum to NVCT in EGFR Lung Cancer - TipRanks
The Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rush - TipRanks
Nuvectis Pharma Inc (NVCT) News, Articles, Events & Latest Updates - Stocktwits
Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High? - Yahoo Finance
Roth MKM Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Maintains Target Price $33 - Moomoo
Nuvectis Pharma Price Target Raised to $33.00/Share From $20.00 by Roth Capital - Moomoo
Roth Capital raises Nuvectis target to $33 - scanx.trade
Roth MKM Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Raises Target Price to $33 - Moomoo
1.80%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):